Results 91 to 100 of about 942,688 (340)

Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations Associated with First-Line Stavudine-Containing Antiretroviral Therapy: Programmatic Implications for Countries Phasing Out Stavudine [PDF]

, 2017
Background The World Health Organization Antiretroviral Treatment Guidelines recommend phasing-out stavudine because of its risk of long-term toxicity. There are two mutational pathways of stavudine resistance with different implications for zidovudine ...
Aghokeng, Avelin, Belec, Laurent, Bertagnolio, Silvia, Bunupuradah, Torsak, Burda, Sherri, Cane, Patricia, Cappelli, Giulia, Charpentier, Charlotte, Dagnra, Anoumou Y., de Wit, Tobias F. Rinke, Deshpande, Alaka K., El-Katib, Ziad, Eshleman, Susan H., Fleury, Herve J., Fokam, Joseph, Ford, Nathan, Gody, Jean-Chrysostome, Hamers, Raph L., Hawkins, Claudia A., Holmes, Susan, Hosseinipour, Mina C., Jordan, Michael R., Kanki, Phyllis J., Katzenstein, David, Koyalta, Donato D., Kumwenda, Johnstone J., Lallemant, Marc, Lynen, Lutgarde, Manosuthi, Weerawat, Marconi, Vincent C., Margot, Nicolas A., Moussa, Sandrine, Ndung'u, Thumbi, Ngo-Giang-Huong, Nicole, Nyambi, Phillipe N., Orrell, Catherine, Peeters, Martine, Rhee, Soo-Yon, Ruxrungtham, Kiat, Schapiro, Jonathan M., Schuurman, Rob, Shafer, Robert W., Sigaloff, Kim C., Sirivichayakul, Sunee, Smith, Davey, Stevens, Wendy, Tang, Michele W., van Zyl, Gert U., Wallis, Carole L., Zolfo, Maria   +49 more
core  

Controlling platinum, ruthenium, and osmium reactivity for anticancer drug design [PDF]

, 2009
The main task of the medicinal chemist is to design molecules that interact specifically with derailed or degenerating processes in a diseased organism, translating the available knowledge of pathobiochemical and physiological data into chemically ...
Bruijnincx, Pieter C. A., Sadler, P. J.
core   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Supplementary Figure S7 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance [PDF]

, 2023
Simone Stupia, Christina Heeke, Alicia Brüggemann, Anne Zaremba, Beatrice Thier, Julia Kretz, Antje Sucker, Manuel Philip, Gennadiy Zelinskyy, Soldano Ferrone, Alexander Roesch, Susanne Horn, Eva Hadaschik, Dirk Schadendorf, Mirko Trilling, Ulf Dittmer, Klaus Griewank, Fang Zhao, Annette Paschen   +18 more
openalex   +1 more source

[Accepted Manuscript] In vitro susceptibility to closthioamide among clinical and reference strains of Neisseria gonorrhoeae. [PDF]

, 2017
Neisseria gonorrhoeae is one of the leading antimicrobial resistance threats worldwide. This study determined the minimum inhibitory concentrations of closthioamide to be 0.008-0.5 mg/L for clinical N. gonorrhoeae strains and related species.
Heap, J.T., Hleba, Y., Miari, V.F., Solanki, P., Stabler, R.A.   +4 more
core   +2 more sources

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Induction of pan-azole resistance in Cryptococcus neoformans by agrochemical azole uniconazole through upregulation of efflux and chromosomal disomies

Frontiers in Cellular and Infection Microbiology
Cryptococcus neoformans is a fungus naturally found in the environment, particularly in soil, bird droppings, and trees. Cryptococcosis, caused by Cryptococcus spp., primarily C. neoformans and C.
Maoji Zhang, Maoji Zhang, Weihua Ma, Jing Wang, Jing Wang, Feng Yang, Jingjing Zhong, Yi Xu, Yi Xu   +8 more
doaj   +1 more source

Possible lack of full cross-resistance of 5HT3 antagonists; a pilot study [PDF]

, 1995
We investigated the potential of cross-over to the serotonin receptor (5HT3) antagonist ondansetron after protection failure with tropisetron. Several cases of complete protection were observed.
Boer, M.F. (Maarten) de, Stoter, G. (Gerrit), Verweij, J. (Jaap), Wit, R. (Ronald) de   +3 more
core   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Unraveling bortezomib resistance in multiple myeloma: insights from RNA-Seq and PI3K/mTOR pathway analysis

Journal of Biological Research
Multiple Myeloma (MM), characterized by abnormal plasma cell proliferation, lacks curative treatment due to drug resistance, notably against Bortezomib, a critical proteasome inhibitor.
Onur Ateş, Yağmur Kiraz
doaj   +1 more source